1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>European Performance Tracker
  4. >>EMA PRIME Scheme

First Lassa Fever Vaccine Wins EMA PRIME Designation; Advanced Therapies Dominate 2024 Entries

 
• By Neena Brizmohun

Two investigational products have made it onto the European Medicines Agency’s priority medicines scheme so far this year. Meanwhile, of the 14 products that entered the scheme last year, six were advanced therapies.

Lassa fever viruses, 3D illustration
There are no approved vaccines for Lassa fever (Shutterstock)
Key Takeaways
  • IAVI's Lassa fever vaccine candidate and a gene therapy for RAG1 deficient severe combined immunodeficiency are the first two products to enter the European Medicines Agency’s PRIME (priority medicines) scheme this year.
  • A total of 14 products made it onto the scheme last year, and 39 applications for PRIME designation were denied.
  • Six of the 14 products last year were advanced therapies.

IAVI’s rVSVdeltaG-LASV-GPC, which is the first Lassa fever vaccine candidate to be evaluated in a Phase II trial, is among the first two products in 2025 to secure a place...

Meanwhile, in 2024, a total of 14 products made it onto the scheme, down from the 18 products accepted in 2022, but higher than the all-time low of 13 products...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from EMA PRIME Scheme

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

First Lassa Fever Vaccine Wins EMA PRIME Designation; Advanced Therapies Dominate 2024 Entries

 
• By Neena Brizmohun

Two investigational products have made it onto the European Medicines Agency’s priority medicines scheme so far this year. Meanwhile, of the 14 products that entered the scheme last year, six were advanced therapies.

EU Approvals

Products containing new active substances that have been approved for marketing in the EU under the EU’s centralized authorization procedure. Updated monthly.

More from Geography

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.